Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 163,835,451 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 96,294,886 shares Gamida Cell Ltd. (GMDA) fell 39.0% to $0.0361 on volume of 89,181,214 sh...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 161,901,639 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 91,101,164 shares Biodexa Pharmaceuticals plc (BDRX) rose 88.6% to $1.62 on volume of 87,7...
A look at the top 10 most actives in the United States Akanda Corp. (AKAN) rose 54.8% to $0.2552 on volume of 35,107,796 shares Nikola Corporation (NKLA) rose 5.0% to $0.9546 on volume of 25,515,019 shares Biodexa Pharmaceuticals plc (BDRX) rose 83.9% to $1.58 on volume of 24,185,655 shar...
2024-03-28 09:59:09 ET DENVER, Colo., Mar 28, 2024 ( 247marketnews.com )- Trump Media & Technology Group (NASDAQ:DJT), iBio, Inc. (NYSEAMERICAN: IBIO ), Xilio Therapeutics, Inc. (NASDAQ: XLO ) Biodexa Pharmaceuticals (NASDAQ: BDRX ), and Bre...
Topline Results For Progression-Free Survival Expected In Q2 2024 CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ("Biodexa"), an acquisition-focused biopharmaceutical company, is developing MTX110 for the treatment of Diffuse Midline Glioma (DMG) in pedia...
2024-03-18 16:46:20 ET More on Biodexa Pharmaceuticals Biodexa stock slides 7% amid data for two drug studies Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earning...
Orally dosed small molecule candidate is designed to reduce/eliminate need for injectable insulin Topline data from Phase 2a program expected by year-end Safety profile established in more than 700 patients CARDIFF, UK / ACCESSWIRE / March 1, 2024 / While type 2 diabetes is frequen...
2024-02-23 10:07:51 ET More on Biodexa Pharmaceuticals Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Biodexa jumps on licensing deal for diabetes candidate Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earning...
2024-02-23 10:07:51 ET More on Biodexa Pharmaceuticals Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Biodexa jumps on licensing deal for diabetes candidate Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earning...
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall Survival of 16.5 Months vs 10.0 months in Comparable Coho...
News, Short Squeeze, Breakout and More Instantly...
Biodexa Pharmaceuticals PLC-ADR Company Name:
BDRX Stock Symbol:
NASDAQ Market:
Biodexa Pharmaceuticals PLC-ADR Website:
July 19, 2024 Biodexa Pharmaceuticals PLC Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage ...
July 16, 2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innov...
2024-07-12 06:42:00 ET 3 Top Tips for Trading Penny Stocks During High Market Volatility Trading penny stocks during periods of high market volatility can be both challenging and rewarding. One crucial tip is to maintain a well-structured trading plan. Establish clear entry and exit...